347 Efficacy and safety of niraparib in older patients (PTS) with advanced ovarian cancer (OC): results from the prima/ENGOT-OV26/GOG-3012 trial
Hanna Dahlstrand, Bhavana Pothuri, Whitney Graybill, Thibault de La Motte Rouge, Colleen Mccormick, Florian Heitz, Jean-Francois Baurain, LI Yong, Bradley J Monk, Antonio González-Martin
51.1%) or not (n= 46, 48.9%) according to Samson and Scott criteria. Chi-squared test, t-test, and univariate/multivariate Cox regression were used. Survival curves were plotted via the Kaplan-Meier method, whilst survival differences were examined via the log-rank test for categorical variables or Cox regression for continuous variables. All reported p-values were two-tailed. Statistical significance was set at p-value <0.05. The statistical analysis was performed using Stata version 16.1
... a Corporation, TX, USA). Results Women with OCCC arising from endometriosis had significantly lower levels of pre-operative CA-125 (434.63 ± 1135.57 Vs 867.30 ± 1609.67, p-value=0.02) and significantly lower incidence of post-operative residual disease (RD) (p-value=0.02). Age, post-menopausal status, FIGO stage and incidence of capsule rupture were not statistically significant. The mean overall survival (OS) and overall progression free survival ( PFS) were 86.35 (95% CI 69.47 -103.22) and 115.97 (95% CI 98.77 -133.17) months, respectively. The presence of endometriosis did not affect neither the OS (87.99 Vs 75.30, p-value=0.25) nor the PFS (111.13 Vs 117.42, p-value=0.48). In univariate analysis, the FIGO stage II-IV and RD were correlated with poorer OS, whilst capsule rupture (CR) with poorer PFS. In multivariate analysis, FIGO stage [HR=2.86 (95% CI 1.47 -5.55), p-value=0.002] and RD [HR=2.52 (95% CI 1.28 -4.94, p-value=0.007) were found independent predictors for OS, whilst CR [HR=0.3 (95% CI 0.11 -0.82), p-value=0.02] for PFS, respectively. No factors affected OS after stratification by stage. Conclusion In this cohort concurrent endometriosis was not a predictive factor for the survival of OCCC women. Further studies are warranted to ascertain whether OCCC with or without coexisting endometriosis develop via distinct pathogenic pathways. Disclosures Nil to disclose. Abstract 347 Table 1 Abstracts Int J Gynecol Cancer 2020;30(Suppl 4):A1-A119 A69 on December 6, 2020 by guest. Protected by copyright.